Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.
Explore premium data & analytics
Products and Services
Products |
---|
Pipeline |
Omecamtiv Mecarbil: Heart Failure |
Reldesemtiv: Spinal Muscular Atrophy and Chronic Obstructive Pulmonary Disease |
XXX |
XXX |
XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2022 | Contracts/Agreements | In May, the company and The ALS Association announced the continuation of their partnership in the fight against ALS. |
2022 | Regulatory Approval | In February, the company secured FDA approval for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction. |
2022 | Contracts/Agreements | In February, the company and the American Heart Association (AHA) Bay Area entered into a collaboration to accelerate education and awareness of heart disease. |
Competitor Comparison
Key Parameters | Cytokinetics Inc | Regeneron Pharmaceuticals Inc | Alexion Pharmaceuticals Inc | Mitsubishi Tanabe Pharma Corp | PTC Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | Japan | United States of America |
City | South San Francisco | Tarrytown | Boston | Osaka | South Plainfield |
State/Province | California | New York | Massachusetts | Osaka | New Jersey |
No. of Employees | 253 | 10,368 | 3,837 | 6,728 | 1,252 |
Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth

Net Income Growth





Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
John T. Henderson, M.D. | Chairman | Executive Board | 2022 | 77 |
Robert I. Blum | President; Director; Chief Executive Officer | Executive Board | 2007 | 58 |
Ching W. Jaw | Senior Vice President; Chief Financial Officer | Senior Management | 2017 | 59 |
Robert C. Wong | Vice President; Chief Accounting Officer | Senior Management | 2019 | 55 |
Kari K. Loeser | Chief Compliance Officer; Vice President | Senior Management | 2021 | - |
Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer